Development of muscle weakness in a mouse model of critical illness: does fibroblast growth factor 21 play a role?
Autophagy
Critical illness
Endoplasmic reticulum stress
FGF21
Mitochondrial function
Muscle mass
Muscle weakness
Journal
Skeletal muscle
ISSN: 2044-5040
Titre abrégé: Skelet Muscle
Pays: England
ID NLM: 101561193
Informations de publication
Date de publication:
04 08 2023
04 08 2023
Historique:
received:
10
01
2023
accepted:
09
06
2023
medline:
7
8
2023
pubmed:
4
8
2023
entrez:
3
8
2023
Statut:
epublish
Résumé
Critical illness is hallmarked by severe stress and organ damage. Fibroblast growth factor 21 (FGF21) has been shown to rise during critical illness. FGF21 is a pleiotropic hormone that mediates adaptive responses to tissue injury and repair in various chronic pathological conditions. Animal studies have suggested that the critical illness-induced rise in FGF21 may to a certain extent protect against acute lung, liver, kidney and brain injury. However, FGF21 has also been shown to mediate fasting-induced loss of muscle mass and force. Such loss of muscle mass and force is a frequent problem of critically ill patients, associated with adverse outcome. In the present study, we therefore investigated whether the critical illness-induced acute rise in FGF21 is muscle-protective or rather contributes to the pathophysiology of critical illness-induced muscle weakness. In a catheterised mouse model of critical illness induced by surgery and sepsis, we first assessed the effects of genetic FGF21 inactivation, and hence the inability to acutely increase FGF21, on survival, body weight, muscle wasting and weakness, and markers of muscle cellular stress and dysfunction in acute (30 h) and prolonged (5 days) critical illness. Secondly, we assessed whether any effects were mirrored by supplementing an FGF21 analogue (LY2405319) in prolonged critical illness. FGF21 was not required for survival of sepsis. Genetic FGF21 inactivation aggravated the critical illness-induced body weight loss (p = 0.0003), loss of muscle force (p = 0.03) and shift to smaller myofibers. This was accompanied by a more pronounced rise in markers of endoplasmic reticulum stress in muscle, without effects on impairments in mitochondrial respiratory chain enzyme activities or autophagy activation. Supplementing critically ill mice with LY2405319 did not affect survival, muscle force or weight, or markers of muscle cellular stress/dysfunction. Endogenous FGF21 is not required for sepsis survival, but may partially protect muscle force and may reduce cellular stress in muscle. Exogenous FGF21 supplementation failed to improve muscle force or cellular stress, not supporting the clinical applicability of FGF21 supplementation to protect against muscle weakness during critical illness.
Sections du résumé
BACKGROUND
Critical illness is hallmarked by severe stress and organ damage. Fibroblast growth factor 21 (FGF21) has been shown to rise during critical illness. FGF21 is a pleiotropic hormone that mediates adaptive responses to tissue injury and repair in various chronic pathological conditions. Animal studies have suggested that the critical illness-induced rise in FGF21 may to a certain extent protect against acute lung, liver, kidney and brain injury. However, FGF21 has also been shown to mediate fasting-induced loss of muscle mass and force. Such loss of muscle mass and force is a frequent problem of critically ill patients, associated with adverse outcome. In the present study, we therefore investigated whether the critical illness-induced acute rise in FGF21 is muscle-protective or rather contributes to the pathophysiology of critical illness-induced muscle weakness.
METHODS
In a catheterised mouse model of critical illness induced by surgery and sepsis, we first assessed the effects of genetic FGF21 inactivation, and hence the inability to acutely increase FGF21, on survival, body weight, muscle wasting and weakness, and markers of muscle cellular stress and dysfunction in acute (30 h) and prolonged (5 days) critical illness. Secondly, we assessed whether any effects were mirrored by supplementing an FGF21 analogue (LY2405319) in prolonged critical illness.
RESULTS
FGF21 was not required for survival of sepsis. Genetic FGF21 inactivation aggravated the critical illness-induced body weight loss (p = 0.0003), loss of muscle force (p = 0.03) and shift to smaller myofibers. This was accompanied by a more pronounced rise in markers of endoplasmic reticulum stress in muscle, without effects on impairments in mitochondrial respiratory chain enzyme activities or autophagy activation. Supplementing critically ill mice with LY2405319 did not affect survival, muscle force or weight, or markers of muscle cellular stress/dysfunction.
CONCLUSIONS
Endogenous FGF21 is not required for sepsis survival, but may partially protect muscle force and may reduce cellular stress in muscle. Exogenous FGF21 supplementation failed to improve muscle force or cellular stress, not supporting the clinical applicability of FGF21 supplementation to protect against muscle weakness during critical illness.
Identifiants
pubmed: 37537627
doi: 10.1186/s13395-023-00320-4
pii: 10.1186/s13395-023-00320-4
pmc: PMC10401744
doi:
Substances chimiques
fibroblast growth factor 21
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
12Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Vanhorebeek I, Latronico N, Van den Berghe G. ICU-acquired weakness. Intensive Care Med. 2020;46(4):637–53. https://doi.org/10.1007/s00134-020-05944-4 .
doi: 10.1007/s00134-020-05944-4
pubmed: 32076765
pmcid: 7224132
Sakr Y, Lobo SM, Moreno RP, Gerlach H, Ranieri VM, Michalopoulos A, et al. Patterns and early evolution of organ failure in the intensive care unit and their relation to outcome. Crit Care. 2012;16(6):R222. https://doi.org/10.1186/cc11868 .
doi: 10.1186/cc11868
pubmed: 23158219
pmcid: 3672601
Viglianti EM, Kramer R, Admon AJ, Sjoding MW, Hodgson CL, Bellomo R, et al. Late organ failures in patients with prolonged intensive care unit stays. J Crit Care. 2018;46:55–7. https://doi.org/10.1016/j.jcrc.2018.03.029 .
doi: 10.1016/j.jcrc.2018.03.029
pubmed: 29684773
pmcid: 6014899
Friedrich O, Reid MB, Van den Berghe G, Vanhorebeek I, Hermans G, Rich MM, et al. The sick and the weak: neuropathies/myopathies in the critically ill. Physiol Rev. 2015;95(3):1025–109. https://doi.org/10.1152/physrev.00028.2014 .
doi: 10.1152/physrev.00028.2014
pubmed: 26133937
pmcid: 4491544
Thiessen SE, Van den Berghe G, Vanhorebeek I. Mitochondrial and endoplasmic reticulum dysfunction and related defense mechanisms in critical illness-induced multiple organ failure. Biochim Biophys Acta Mol Basis Dis. 2017;1863(10 Pt B):2534–45. https://doi.org/10.1016/j.bbadis.2017.02.015 .
BonDurant LD, Potthoff MJ. Fibroblast growth factor 21: a versatile regulator of metabolic homeostasis. Annu Rev Nutr. 2018;38:173–96. https://doi.org/10.1146/annurev-nutr-071816-064800 .
doi: 10.1146/annurev-nutr-071816-064800
pubmed: 29727594
pmcid: 6964258
Salminen A, Kaarniranta K, Kauppinen A. Integrated stress response stimulates FGF21 expression: Systemic enhancer of longevity. Cell Signal. 2017;40:10–21. https://doi.org/10.1016/j.cellsig.2017.08.009 .
doi: 10.1016/j.cellsig.2017.08.009
pubmed: 28844867
Ji K, Zheng J, Lv J, Xu J, Ji X, Luo YB, et al. Skeletal muscle increases FGF21 expression in mitochondrial disorders to compensate for energy metabolic insufficiency by activating the mTOR-YY1-PGC1alpha pathway. Free Radic Biol Med. 2015;84:161–70. https://doi.org/10.1016/j.freeradbiomed.2015.03.020 .
doi: 10.1016/j.freeradbiomed.2015.03.020
pubmed: 25843656
Kim KH, Jeong YT, Oh H, Kim SH, Cho JM, Kim YN, et al. Autophagy deficiency leads to protection from obesity and insulin resistance by inducing Fgf21 as a mitokine. Nat Med. 2013;19(1):83–92. https://doi.org/10.1038/nm.3014 .
doi: 10.1038/nm.3014
Kim SH, Kim KH, Kim HK, Kim MJ, Back SH, Konishi M, et al. Fibroblast growth factor 21 participates in adaptation to endoplasmic reticulum stress and attenuates obesity-induced hepatic metabolic stress. Diabetologia. 2015;58(4):809–18. https://doi.org/10.1007/s00125-014-3475-6 .
doi: 10.1007/s00125-014-3475-6
pubmed: 25537833
Wang L, Ishihara T, Ibayashi Y, Tatsushima K, Setoyama D, Hanada Y, et al. Disruption of mitochondrial fission in the liver protects mice from diet-induced obesity and metabolic deterioration. Diabetologia. 2015;58(10):2371–80. https://doi.org/10.1007/s00125-015-3704-7 .
doi: 10.1007/s00125-015-3704-7
pubmed: 26233250
Mraz M, Bartlova M, Lacinova Z, Michalsky D, Kasalicky M, Haluzikova D, et al. Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity. Clin Endocrinol (Oxf). 2009;71(3):369–75. https://doi.org/10.1111/j.1365-2265.2008.03502.x .
doi: 10.1111/j.1365-2265.2008.03502.x
pubmed: 19702724
Lee JH, Kang YE, Chang JY, Park KC, Kim HW, Kim JT, et al. An engineered FGF21 variant, LY2405319, can prevent non-alcoholic steatohepatitis by enhancing hepatic mitochondrial function. Am J Transl Res. 2016;8(11):4750–63.
pubmed: 27904677
pmcid: 5126319
Zhu S, Wu Y, Ye X, Ma L, Qi J, Yu D, et al. FGF21 ameliorates nonalcoholic fatty liver disease by inducing autophagy. Mol Cell Biochem. 2016;420(1–2):107–19. https://doi.org/10.1007/s11010-016-2774-2 .
doi: 10.1007/s11010-016-2774-2
pubmed: 27435856
Tezze C, Romanello V, Sandri M. FGF21 as modulator of metabolism in health and disease. Front Physiol. 2019;10:419. https://doi.org/10.3389/fphys.2019.00419 .
doi: 10.3389/fphys.2019.00419
pubmed: 31057418
pmcid: 6478891
Kohara M, Masuda T, Shiizaki K, Akimoto T, Watanabe Y, Honma S, et al. Association between circulating fibroblast growth factor 21 and mortality in end-stage renal disease. PLoS One. 2017;12(6):e0178971. https://doi.org/10.1371/journal.pone.0178971 .
Chou RH, Huang PH, Hsu CY, Chang CC, Leu HB, Huang CC, et al. Circulating fibroblast growth factor 21 is associated with diastolic dysfunction in heart failure patients with preserved ejection fraction. Sci Rep. 2016;6:33953. https://doi.org/10.1038/srep33953 .
doi: 10.1038/srep33953
pubmed: 27650781
pmcid: 5030655
Oost LJ, Kustermann M, Armani A, Blaauw B, Romanello V. Fibroblast growth factor 21 controls mitophagy and muscle mass. J Cachexia Sarcopenia Muscle. 2019;10(3):630–42. https://doi.org/10.1002/jcsm.12409 .
doi: 10.1002/jcsm.12409
pubmed: 30895728
pmcid: 6596457
Tezze C, Romanello V, Desbats MA, Fadini GP, Albiero M, Favaro G, et al. Age-associated loss of OPA1 in muscle impacts muscle mass, metabolic homeostasis, systemic inflammation, and epithelial senescence. Cell Metab. 2017;25(6):1374-89.e6. https://doi.org/10.1016/j.cmet.2017.04.021 .
doi: 10.1016/j.cmet.2017.04.021
pubmed: 28552492
pmcid: 5462533
Thiessen SE, Vanhorebeek I, Derese I, Gunst J, Van den Berghe G. FGF21 Response to critical illness: effect of blood glucose control and relation with cellular stress and survival. J Clin Endocrinol Metab. 2015;100(10):E1319–27. https://doi.org/10.1210/jc.2015-2700 .
doi: 10.1210/jc.2015-2700
pubmed: 26274346
Gariani K, Drifte G, Dunn-Siegrist I, Pugin J, Jornayvaz FR. Increased FGF21 plasma levels in humans with sepsis and SIRS. Endocr Connect. 2013;2(3):146–53. https://doi.org/10.1530/EC-13-0040 .
doi: 10.1530/EC-13-0040
pubmed: 23999826
pmcid: 3845842
Feingold KR, Grunfeld C, Heuer JG, Gupta A, Cramer M, Zhang T, et al. FGF21 is increased by inflammatory stimuli and protects leptin-deficient ob/ob mice from the toxicity of sepsis. Endocrinology. 2012;153(6):2689–700. https://doi.org/10.1210/en.2011-1496 .
doi: 10.1210/en.2011-1496
pubmed: 22474187
pmcid: 3359613
Wang A, Huen SC, Luan HH, Yu S, Zhang C, Gallezot DJ, et al. Opposing effects of fasting metabolism on tissue tolerance in bacterial and viral inflammation. Cell. 2016;166:1512–25. https://doi.org/10.1016/j.cell.2016.07.026 .
doi: 10.1016/j.cell.2016.07.026
pubmed: 27610573
pmcid: 5555589
Li JY, Wang N, Khoso MH, Shen CB, Guo MZ, Pang XX, et al. FGF-21 Elevated IL-10 production to correct LPS-induced inflammation. Inflammation. 2018;41(3):751–9. https://doi.org/10.1007/s10753-018-0729-3 .
doi: 10.1007/s10753-018-0729-3
pubmed: 29427162
Gao J, Liu Q, Li J, Hu C, Zhao W, Ma W, et al. Fibroblast Growth Factor 21 dependent TLR4/MYD88/NF-kappaB signaling activation is involved in lipopolysaccharide-induced acute lung injury. Int Immunopharmacol. 2020;80:106219. https://doi.org/10.1016/j.intimp.2020.106219 .
Chen J, Hu J, Liu H, Xiong Y, Zou Y, Huang W, et al. FGF21 protects the blood-brain barrier by upregulating PPARgamma via FGFR1/beta-klotho after traumatic brain injury. J Neurotrauma. 2018;35(17):2091–103. https://doi.org/10.1089/neu.2017.5271 .
doi: 10.1089/neu.2017.5271
pubmed: 29648978
Shahror RA, Linares GR, Wang Y, Hsueh SC, Wu CC, Chuang DM, et al. Transplantation of mesenchymal stem cells overexpressing fibroblast growth factor 21 facilitates cognitive recovery and enhances neurogenesis in a mouse model of traumatic brain injury. J Neurotrauma. 2020;37(1):14–26. https://doi.org/10.1089/neu.2019.6422 .
doi: 10.1089/neu.2019.6422
pubmed: 31298621
Ye D, Wang Y, Li H, Jia W, Man K, Lo CM, et al. Fibroblast growth factor 21 protects against acetaminophen-induced hepatotoxicity by potentiating peroxisome proliferator-activated receptor coactivator protein-1alpha-mediated antioxidant capacity in mice. Hepatology. 2014;60(3):977–89. https://doi.org/10.1002/hep.27060 .
doi: 10.1002/hep.27060
pubmed: 24590984
Yu Y, Bai F, Liu Y, Yang Y, Yuan Q, Zou D, et al. Fibroblast growth factor (FGF21) protects mouse liver against D-galactose-induced oxidative stress and apoptosis via activating Nrf2 and PI3K/Akt pathways. Mol Cell Biochem. 2015;403(1–2):287–99. https://doi.org/10.1007/s11010-015-2358-6 .
doi: 10.1007/s11010-015-2358-6
pubmed: 25701356
Li F, Liu Z, Tang C, Cai J, Dong Z. FGF21 is induced in cisplatin nephrotoxicity to protect against kidney tubular cell injury. FASEB J. 2018;32(6):3423–33. https://doi.org/10.1096/fj.201701316R .
doi: 10.1096/fj.201701316R
pubmed: 29401620
pmcid: 5956244
Chen Q, Ma J, Yang X, Li Q, Lin Z, Gong F. SIRT1 mediates effects of FGF21 to ameliorate cisplatin-induced acute kidney injury. Front Pharmacol. 2020;10(11):241. https://doi.org/10.3389/fphar.2020.00241 .
doi: 10.3389/fphar.2020.00241
Derde S, Thiessen S, Goossens C, Dufour T, Van den Berghe G, Langouche L. Use of a central venous line for fluids, drugs and nutrient administration in a mouse model of critical illness. J Vis Exp. 2017(123). https://doi.org/10.3791/55553 .
Marques M, Vander Perre S, Aertgeerts A, Derde S, Guiza F, Casaer MP, et al. Critical illness induces nutrient-independent adipogenesis and accumulation of alternatively activated tissue macrophages. Crit Care. 2013;17(5):R193. https://doi.org/10.1186/cc12887 .
doi: 10.1186/cc12887
pubmed: 24020372
pmcid: 4056380
Langford DJ, Bailey AL, Chanda ML, Clarke SE, Drummond TE, Echols S, et al. Coding of facial expressions of pain in the laboratory mouse. Nat Methods. 2010;7(6):447–9. https://doi.org/10.1038/nmeth.1455 .
doi: 10.1038/nmeth.1455
pubmed: 20453868
Potthoff MJ, Inagaki T, Satapati S, Ding X, He T, Goetz R, et al. FGF21 induces PGC-1alpha and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response. Proc Natl Acad Sci U S A. 2009;106(26):10853–8. https://doi.org/10.1073/pnas.0904187106 .
doi: 10.1073/pnas.0904187106
pubmed: 19541642
pmcid: 2705613
Goossens C, Marques MB, Derde S, Vander Perre S, Dufour T, Thiessen SE, et al. Premorbid obesity, but not nutrition, prevents critical illness-induced muscle wasting and weakness. J Cachexia Sarcopenia Muscle. 2017;8(1):89–101. https://doi.org/10.1002/jcsm.12131 .
doi: 10.1002/jcsm.12131
pubmed: 27897405
Goossens C, Weckx R, Derde S, Dufour T, Vander Perre S, Pauwels L, et al. Adipose tissue protects against sepsis-induced muscle weakness in mice: from lipolysis to ketones. Crit Care. 2019;23:236. https://doi.org/10.1186/s13054-019-2506-6 .
doi: 10.1186/s13054-019-2506-6
pubmed: 31262340
pmcid: 6600878
Kharitonenkov A, Beals JM, Micanovic R, Strifler BA, Rathnachalam R, Wroblewski VJ, et al. Rational design of a fibroblast growth factor 21-based clinical candidate, LY2405319. PLoS One. 2013;8(3):e58575. https://doi.org/10.1371/journal.pone.0058575 .
Vanhorebeek I, De Vos R, Mesotten D, Wouters PJ, De Wolf-Peeters C, Van den Berghe G. Protection of hepatocyte mitochondrial ultrastructure and function by strict blood glucose control with insulin in critically ill patients. Lancet. 2005;365(9453):53–9. https://doi.org/10.1016/S0140-6736(04)17665-4 .
doi: 10.1016/S0140-6736(04)17665-4
pubmed: 15639679
Li X, Zhu Z, Zhou T, Cao X, Lu T, Liang Y, et al. Early increases in serum FGF21 levels predict mortality of septic patients. Cytokine. 2018;111:428–33. https://doi.org/10.1016/j.cyto.2018.05.020 .
doi: 10.1016/j.cyto.2018.05.020
pubmed: 29861384
Fazeli PK, Lun M, Kim SM, Bredella MA, Wright S, Zhang Y, et al. FGF21 and the late adaptive response to starvation in humans. J Clin Invest. 2015;125(12):4601–11. https://doi.org/10.1172/JCI83349 .
doi: 10.1172/JCI83349
pubmed: 26529252
pmcid: 4665770
Solon-Biet SM, Cogger VC, Pulpitel T, Heblinski M, Wahl D, McMahon AC, et al. Defining the nutritional and metabolic context of FGF21 using the geometric framework. Cell Metab. 2016;24(4):555–65. https://doi.org/10.1016/j.cmet.2016.09.001 .
doi: 10.1016/j.cmet.2016.09.001
pubmed: 27693377
Inagaki T, Dutchak P, Zhao G, Ding X, Gautron L, Parameswara V, et al. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab. 2007;5(6):415–25. https://doi.org/10.1016/j.cmet.2007.05.003 .
doi: 10.1016/j.cmet.2007.05.003
pubmed: 17550777
Laeger T, Henagan TM, Albarado DC, Redman LM, Bray GA, Noland RC, et al. FGF21 is an endocrine signal of protein restriction. J Clin Invest. 2014;124(9):3913–22. https://doi.org/10.1172/JCI74915 .
doi: 10.1172/JCI74915
pubmed: 25133427
pmcid: 4153701
Xu J, Lloyd DJ, Hale C, Stanislaus S, Chen M, Sivits G, et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes. 2009;58(1):250–9. https://doi.org/10.2337/db08-0392 .
doi: 10.2337/db08-0392
pubmed: 18840786
pmcid: 2606881
Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ, et al. FGF-21 as a novel metabolic regulator. J Clin Invest. 2005;115(6):1627–35. https://doi.org/10.1172/JCI23606 .
doi: 10.1172/JCI23606
pubmed: 15902306
pmcid: 1088017
Qaisar R, Bhaskaran S, Van Remmen H. Muscle fiber type diversification during exercise and regeneration. Free Radic Biol Med. 2016;98:56–67. https://doi.org/10.1016/j.freeradbiomed.2016.03.025 .
doi: 10.1016/j.freeradbiomed.2016.03.025
pubmed: 27032709
Afroze D, Kumar A. ER stress in skeletal muscle remodeling and myopathies. FEBS J. 2019;286(2):379–98. https://doi.org/10.1111/febs.14358 .
doi: 10.1111/febs.14358
pubmed: 29239106
Fisher FM, Estall JL, Adams AC, Antonellis PJ, Bina HA, Flier JS, et al. Integrated regulation of hepatic metabolism by fibroblast growth factor 21 (FGF21) in vivo. Endocrinology. 2011;152(8):2996–3004. https://doi.org/10.1210/en.2011-0281 .
doi: 10.1210/en.2011-0281
pubmed: 21712364
pmcid: 3138239
Benoit B, Meugnier E, Castelli M, Chanon S, Vieille-Marchiset A, Durand C, et al. Fibroblast growth factor 19 regulates skeletal muscle mass and ameliorates muscle wasting in mice. Nat Med. 2017;23(8):990–6. https://doi.org/10.1038/nm.4363 .
doi: 10.1038/nm.4363
pubmed: 28650457
Jeon JY, Choi SE, Ha ES, Kim TH, Jung JG, Han SJ, et al. Association between insulin resistance and impairment of FGF21 signal transduction in skeletal muscles. Endocrine. 2016;53(1):97–106. https://doi.org/10.1007/s12020-015-0845-x .
doi: 10.1007/s12020-015-0845-x
pubmed: 26758997
Vandanmagsar B, Warfel JD, Wicks SE, Ghosh S, Salbaum JM, Burk D, Dubuisson OS, et al. Impaired mitochondrial fat oxidation induces FGF21 in muscle. Cell Rep. 2016;15(8):1686–99. https://doi.org/10.1016/j.celrep.2016.04.057 .
doi: 10.1016/j.celrep.2016.04.057
pubmed: 27184848
pmcid: 4880522
Xiong Y, Chen Y, Liu Y, Zhang B. Moderate-intensity continuous training improves FGF21 and KLB expression in obese mice. Biochemistry (Mosc). 2020;85(8):938–46. https://doi.org/10.1134/S000629792008009X .
doi: 10.1134/S000629792008009X
pubmed: 33045954
Ito S, Kinoshita S, Shiraishi N, Nakagawa S, Sekine S, Fujimori T, et al. Molecular cloning and expression analyses of mouse betaklotho, which encodes a novel Klotho family protein. Mech Dev. 2000;98(1–2):115–9. https://doi.org/10.1016/s0925-4773(00)00439-1 .
doi: 10.1016/s0925-4773(00)00439-1
pubmed: 11044614
Barbosa-Morais NL, Irimia M, Pan Q, Xiong HY, Gueroussov S, Lee LJ, et al. The evolutionary landscape of alternative splicing in vertebrate species. Science. 2012;338(6114):1587–93. https://doi.org/10.1126/science.1230612 .
doi: 10.1126/science.1230612
pubmed: 23258890
ArrayExpress experiment E-MTAB-2801 – GEO: GSE41637 by Merkin J, Burge C. Strand-specific RNA-seq of nine mouse tissues.
Sun H, Sherrier M, Li H. Skeletal muscle and bone – emerging targets of fibroblast growth factor-21. Front Physiol. 2021;12:625287. https://doi.org/10.3389/fphys.2021.625287 .
Liu X, Wang Y, Zhao S, Li X. Fibroblast growth factor 21 promotes C2C12 cells myogenic differentiation by enhancing cell cycle exit. Biomed Res Int. 2017;2017:1648715. https://doi.org/10.1155/2017/1648715 .
doi: 10.1155/2017/1648715
pubmed: 29109955
pmcid: 5646352
Ji K, Zheng J, Lv J, Xu J, Ji X, Luo Y-B, et al. Skeletal muscle increases FGF21 expression in mitochondrial disorders to compensate for energy metabolic insufficiency by activating the mTOR-YY1-PGC1α pathway. Free Radic Biol Med. 2015;84:161–70. https://doi.org/10.1016/j.freeradbiomed.2015.03.020 .
doi: 10.1016/j.freeradbiomed.2015.03.020
pubmed: 25843656
Ma L, Zhang C, Gui Y, Zou T, Xi S, Guo X. Fluoride regulates the differentiation and atrophy through FGF21/ERK signaling pathway in C2C12 cells. Ecotoxicol Environ Saf. 2023;252:114626. https://doi.org/10.1016/j.ecoenv.2023.114626 .
Li B, Liu L. Fibroblast growth factor 21, a stress regulator, inhibits Drp1 activation to alleviate skeletal muscle ischemia/reperfusion injury. Lab Invest. 2022;102(9):979–88. https://doi.org/10.1038/s41374-022-00787-7 .
doi: 10.1038/s41374-022-00787-7
pubmed: 35488034
Rosales-Soto G, Diaz-Vegas A, Casas M, Contreras-Ferrat A, Jaimovich E. Fibroblast growth factor-21 potentiates glucose transport in skeletal muscle fibers. J Mol Endocrinol. 2020;JME-19–0210.R2. https://doi.org/10.1530/JME-19-0210 .
Mashili FL, Austin RL, Deshmukh AS, Fritz T, Caidahl K, Bergdahl K, et al. Direct effects of FGF21 on glucose uptake in human skeletal muscle: implications for type 2 diabetes and obesity. Diabetes Metab Res Rev. 2011;27(3):286–97. https://doi.org/10.1002/dmrr.1177 .
doi: 10.1002/dmrr.1177
pubmed: 21309058
Kim C-S, Joe Y, Choi H-S, Back SH, Park JW, Chung HT. Deficiency of fibroblast growth factor 21 aggravates obesity-induced atrophic responses in skeletal muscle. J Inflamm (Lond). 20194;16:17. doi: https://doi.org/10.1186/s12950-019-0221-3 .
Wang X, Zhu L, Hu J, Guo R, Ye S, Liu F, et al. FGF21 Attenuated LPS-induced depressive-like behavior via inhibiting the inflammatory pathway. Front Pharmacol. 2020;11:154. https://doi.org/10.3389/fphar.2020.00154 .
doi: 10.3389/fphar.2020.00154
pubmed: 32184729
pmcid: 7058797
Yang X, Hui Q, Yu B, Huang Z, Zhou P, Wang P, et al. Design and evaluation of lyophilized fibroblast growth factor 21 and its protection against ischemia cerebral injury. Bioconjug Chem. 2018;29(2):287–95. https://doi.org/10.1021/acs.bioconjchem.7b00588 .
doi: 10.1021/acs.bioconjchem.7b00588
pubmed: 29278321
Ye L, Wang X, Cai C, Zeng S, Bai J, Guo K, et al. FGF21 promotes functional recovery after hypoxic-ischemic brain injury in neonatal rats by activating the PI3K/Akt signaling pathway via FGFR1/beta-klotho. Exp Neurol. 2019;317:34–50. https://doi.org/10.1016/j.expneurol.2019.02.013 .
doi: 10.1016/j.expneurol.2019.02.013
pubmed: 30802446
So WY, Cheng Q, Xu A, Lam KS, Leung PS. Loss of fibroblast growth factor 21 action induces insulin resistance, pancreatic islet hyperplasia and dysfunction in mice. Cell Death Dis. 2015;6:e1707. https://doi.org/10.1038/cddis.2015.80 .